New immune combo tackles tough lymphoma
NCT ID NCT07125872
First seen Mar 31, 2026 · Last updated May 13, 2026 · Updated 4 times
Summary
This study tests a new mix of three drugs (CD19 t-haNK, N-803, and rituximab) in 20 adults whose B-cell non-Hodgkin lymphoma has returned or not responded to at least two prior treatments. The goal is to see if this combination can shrink tumors and improve survival. Participants will receive the treatment and be monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Albert Cellular Therapy
RECRUITINGPretoria, 0044, South Africa
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Dr. Jackie Thomson Inc
RECRUITINGJohannesburg, 2193, South Africa
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.